Mind the Tech LONDON 2025

We’re building a force multiplier for maritime and national resilience.
Skana Robotics designs and manufactures autonomous vessels and develops the software stack that connects them into a unified, scalable ecosystem. Covering both surface and sub-surface domains, our mission-ready, software-defined systems orchestrate hybrid autonomous fleets across complex operations. By merging deep operational expertise with end-to-end technological control, we empower modern naval forces to respond with speed, scale, and precision, reshaping maritime resilience.

Critical infrastructure runs on legacy, air-gapped systems where human error is a major driver of costly downtime. Maverick AI's vision is to provide an on-premise AI co-pilot that captures the expertise of a facility's best operator, making it available 24/7 to guide the entire team toward the correct action at all times.

Always Connect AI develops an advanced AI engine that unlocks the full potential of satellite networks by delivering real-time, autonomous multi-orbit optimization. Our technology installs as a lightweight SDK on any device or platform, enabling intelligent management of GEO, MEO, and LEO links without hardware changes. By learning traffic behavior, detecting anomalies, and dynamically routing data, we ensure stable, efficient, mission-critical connectivity for defense, robotics, mobility, and commercial satellite systems.

Re-fresh Global, a Israeli-German materials company, pioneers the SMART-UP SYSTEM, a patented biochemical process to convert textile waste into premium materials at scale, addressing the global textile waste crisis. Annually, 92 million tons of textile waste are discarded worldwide, with current collection methods salvaging only 10-15%. The bulk (85%) ends up in landfills or incinerators, incurring industry losses of over 500 billion USD and significant environmental harm.Re-fresh Global revolutionizes the textile industry by transforming textile waste into high-quality new raw materials (nanocellulose, bioethanol, multifunctional fibers) using a unique upcycling process. Nanocellulose is used for coating, lamination, implants, electronics, and other uses. Bioethanol can be used in any stead of standardly produced ethanol, such as fuel or cosmetics. Multifunctional fibers can be customized for any nonwoven application such as molds, seat coverings, lampshades for the automotive, furniture and other textile-related industries etc. These three products can replace their virgin counterparts, helping manufacturers “go green” and reduce the environmental impact of their products. This groundbreaking upcycling process runs through the SMART-UP URBAN SYSTEM, allowing even small and medium-sized enterprises to use it cost-effectively.

ALVIV is a medical device technology startup bringing impactful innovative laser- based medical solutions for clinics and outpatient settings. Our first breakthrough solution is a fast, pain free, safe laser-based treatment for Fecal Incontinence (FI) patients (globally 9% of the population is affected!!). We are changing FI treatment modality by targeting the clinical problem and not the symptoms only. Our proprietary, pain-free laser therapy restores sphincter function through controlled tissue regeneration, offering a new, safe, and effective treatment pathway. With proven first-in-human results and a scalable outpatient model, ALVIV aims to improve quality of life for millions of patients.

LepreCon’s proprietary technology protects banks and their customers against the fast-growing AI-powered social engineering fraud - a global $1 trillion risk. Lepre Con’s solution predicts fraud before it materializes and blocks it on its first move. Our solution consists of a proprietary psychographic diagnosis based solely on bank data, along with a comprehensive proprietary bank data model. Founded by industry experts, Shlomo Gilead, a former Chief Strategist of a bank and credit card company, and Amir Raskin, a banking data and analytics expert and Co-Founder of HyperRoll (acquired by Oracle).

CURESPONSE is a precision oncology company transforming cancer care and oncology drug development through a breakthrough ex-vivo platform. Originating from the Weizmann Institute, our technology predicts patient response to cancer therapies with over 90% accuracy, guiding oncologists to select the most effective treatment from the outset. Applicable to all solid tumors and all major therapy classes, our test is already used clinically and reimbursed by private insurers. For pharma and biotech, we significantly accelerate R&D by identifying the most promising compounds early, reducing clinical trial costs and failures. With CE-mark approval, we are scaling across Europe and the US.

About LumenGuidesWe are developing Naviscope, the first-ever autonomous, single-use, radiation-free robotic navigation platform for bronchoscopy.Today’s navigation systems fail to reach ~40% of lung nodules, often requiring CT, fluoroscopy, or EMN guidance—all of which are expensive, time-consuming, and expose patients and physicians to radiation.Naviscope changes that:✔️ Fiber-optic sensors (FBG) generate real-time 3D airway mapping from inside the lungs✔️ AI-based robotic guidance navigates independently—no external imaging needed✔️ Single-use, cost-effective, safe, and faster than traditional methods

dot SAGA is building the next-generation safety and communication network for venues. Our wearable devices, private mesh network, and AI-powered command platform ensure real-time connectivity, location tracking, and incident response — even when cellular networks fail. Designed for large-scale events, stadiums, ski resorts, and critical facilities, dot SAGA empowers operators to react instantly, prevent incidents, and manage operations intelligently. With features like PTT-to-text, predictive analytics, and distress alerts, we replace outdated radios with a scalable, data-driven solution that enhances safety, reduces response times, and improves the experience for guests and staff alike.

Datricks is an autonomous solution that eliminates financial exposures such as human errors, non-compliance, and fraud, transforming businesses into beacons of airtight Financial Integrity. Its Financial Integrity Platform enables CFOs to enhance their bottom line, improve working capital, and confidently scale their financial operations, significantly boosting their contribution to organizational growth.

Imagry is pioneering Generative Autonomy: real-time intelligence that drives machines in the physical world. Our platform, Imagry Cortex™, delivers vision-based autonomy without HD maps, LiDAR, or the cloud. Unlike rule-based systems, Cortex learns from experience and adapts to any road, vehicle, or condition, just like a human, only better. Already deployed across transit and fleet vehicles, Imagry is solving the scalability challenge for both public transportation and passenger cars. Our real-time, hardware-agnostic architecture integrates seamlessly with existing platforms, giving automakers and transit operators a cost-effective, production-ready autonomy solution. The next leap in Gen AI isn’t a chatbot. It’s a driver.

RespirAI is a digital health company developing an AI-powered home-monitoring platform to support patients with chronic respiratory diseases. Using continuous, passive data collection from FDA-approved wearable sensors, RespirAI’s platform analyzes multi-parameter physiological signals to detect changes in patients' conditions and generate actionable clinical insights. The initial focus is on chronic obstructive pulmonary disease (COPD), with the goal of improving patient outcomes, reducing hospitalizations and re-admission, and enabling proactive, personalized disease management in both clinical and home settings.

Starget Pharma develops Smart Targeted Radioligands (STRs) for metastatic cancers. Our AI-driven platform rapidly designs peptide radioligands that home to tumors and deliver high-energy radiation inside cancer cells, sparing healthy tissue. Targeted radiotherapy is surging—validated by Novartis’ two approved drugs—and propelled by multibillion-dollar M&A, making radioligands one of oncology’s most attractive frontiers. Backed by $25M and founders of UroGen Pharma (NASDAQ: URGN), our leadership spans peptide engineering, AI, and nuclear medicine. We’re advancing three radioligand candidates entering clinical trials in 2026 across breast, sarcoma, prostate, and cancers. Recognized by Start Us Insights as the #1 Top New Pharma Company to Watch.

QuamCore is an Israeli deep-tech startup founded in 2022, focused on pushing the scalability limits of quantum computing by developing a superconducting quantum-processor architecture designed to support up to one million qubits in a single cryostat. Their key innovations include integrating ultra-low-power superconducting digital control logic directly into the cryogenic environment, drastically reducing cabling and thermal bottlenecks that currently limit quantum systems. The company aims to create fault-tolerant, economically viable quantum systems for real-world applications across AI, materials science, pharmaceuticals and energy.